The financial markets performed well last week rising some 180 points to close at 5,700, whilst the AIM All Share rose 20 points to close at 734 points. Good progress was made with regards to the European debt crisis, and the BoE were unanimous in voting £75bn of quantitative easing. This week, UK economic growth was 0.5% during the third quarter (higher than the 0.4% in the second) and UK retail figures grew by a stronger than expected 0.6% in September, though the announcement of a Greek referendum caused the US and European markets some difficulties. Looking at the week ahead, PMI data from manufacturing, construction and services sectors will be announced.

Disclaimer- This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only- please refer to the disclaimer in full below. 

AMC Resource report, ABH Comment on EU ruling, ANCR Trading update, AVAP Final results, BMY H1 results, CCS New contracts,EDE.PL Acquisition of technology, GGG Corporate and exploration announcements, IVO Funding round, KMR Interim statement,LID Interim results, LRM Interim results, LMR Enters Administration, MDY Asset Sale, MONI Company investment,NGP Valuation Uplift, HAWK Placing, NGL Fund raise, SUN Grant from RGF,  TAN Receives Payment, TRP New contract, XEN update on transformational deals.

 Amur Minerals Corporation (AMC 10.5p / £29.18m)*

The nickel-copper sulphide mineral exploration and resource development company focused on far east Russia announced that the Research Centre of the Institute for Geological Exploration of Base and Precious Metals (TSNIGRI ) has compiled a comprehensive report establishing the value of the projected recovered metals within the complex concentrate of the Company’s Kun-Manie project. The valuation report has been forwarded to the Ministry of Economic Development (MED’s) for its consideration and review as related to Amur’s application for its mining licence.  The MED’s responsibilities include its calculation of the concentrate value or alternatively it can utilise a valuation generated by another federal agency certified by the governmental authorities of the Russian Federation. The market awaits news on the licence nevertheless; however it continues to get good results in its exploration programme in the meantime. 

Angel Biotechnology Holdings (ABH 0.24p / £6.59m)* 

The AIM listed biopharmaceutical contract manufacturer commented on the ruling issued on Tuesday 18th October by the European Court of Justice prohibiting the patentability of human embryonic stem cells. The company said that the court ruling that patents would not…

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here